Rockwell Medical (FRA:RWM) LT-Debt-to-Total-Asset: 0.20 (As of Mar. 2026)

What is Rockwell Medical LT-Debt-to-Total-Asset?

Rockwell Medical FRA:RWM 30 LT-Debt-to-Total-Asset is 0.20 as of Mar. 2026. GuruFocus rates FRA:RWM with a GF Score™ of 30/100 and a GF Value™ of €0.90 (Significantly Overvalued). The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Rockwell Medical's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.20.

Rockwell Medical's long-term debt to total assets ratio increased from Mar. 2025 (0.20) to Mar. 2026 (0.20). It may suggest that Rockwell Medical is progressively becoming more dependent on debt to grow their business.

Rockwell Medical (FRA:RWM) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Rockwell Medical LT-Debt-to-Total-Asset Related Terms

Rockwell Medical LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Rockwell Medical's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rockwell Medical LT-Debt-to-Total-Asset Chart

Rockwell Medical Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.39

0.26

0.22

0.19

Rockwell Medical Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.20	0.21	0.19	0.19	0.20

30GF Score

Rockwell Medical Inc FRA:RWM

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Rockwell Medical LT-Debt-to-Total-Asset Calculation

Rockwell Medical's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	9.039	/	48.802
	=	0.19

Rockwell Medical's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	10.119	/	49.671
	=	0.20

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.20 mean?

Rockwell Medical (FRA:RWM) has a LT-Debt-to-Total-Asset of 0.20 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Rockwell Medical and its competitors.

Is Rockwell Medical's LT-Debt-to-Total-Asset too high?

Rockwell Medical's current LT-Debt-to-Total-Asset is 0.20. Overall, Rockwell Medical has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Rockwell Medical's LT-Debt-to-Total-Asset compare to CPHI and TXMD?

Rockwell Medical's LT-Debt-to-Total-Asset of 0.20 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Rockwell Medical and its competitors. Rockwell Medical's current LT-Debt-to-Total-Asset is 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Rockwell Medical stock overvalued right now?

Based on GuruFocus' analysis, Rockwell Medical (FRA:RWM) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.90, compared to a current price of €5.25 — trading 483.3% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.20. Rockwell Medical's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Rockwell Medical (FRA:RWM), the current LT-Debt-to-Total-Asset is 0.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rockwell Medical (FRA:RWM) Overvalued in 2026?

Based on GuruFocus' analysis, Rockwell Medical stock appears to be overvalued. The current stock price of €5.25 is trading 483.3% above its estimated GF Value™ of €0.90. GuruFocus considers Rockwell Medical to be Significantly Overvalued.

Key valuation signals for FRA:RWM:

LT-Debt-to-Total-Asset: 0.20
GF Value™: €0.90 vs. price of €5.25 (483.3% above fair value)
GF Score™: 30/100 with 3 warning signs

No single metric tells the full story. See the FRA:RWM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rockwell Medical Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies CPHI TXMD MRMD AYTU HYEX ZYBT IGPK KAYS INIS APUS XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges RMTI:USA

Address 30142 South Wixom Road, Wixom, MI, USA, 48393

Website https://www.rockwellmed.com

Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, acid, and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate, among others. The company delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers.

30GF Score

Get the complete analysis for FRA:RWM

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.25

Price

€0.90

GF Value

View FRA:RWM Analysis

See LT-Debt-to-Total-Asset data for all stocks →